- Report
- March 2025
- 1048 Pages
Global
From €4203EUR$4,799USD£3,648GBP
- Report
- September 2025
- 180 Pages
Global
From €1708EUR$1,950USD£1,482GBP
€2627EUR$3,000USD£2,280GBP
- Report
- November 2025
- 139 Pages
Global
From €4073EUR$4,650USD£3,535GBP
- Report
- January 2026
- 197 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 190 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- February 2026
- 267 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 288 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 287 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 382 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 211 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- January 2026
- 196 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 186 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 182 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- January 2026
- 181 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- March 2025
- 182 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- February 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP

The Neoantigen market is a subset of the Genomics market that focuses on the identification and development of neoantigens for use in cancer immunotherapy. Neoantigens are proteins that are produced by tumor cells and are recognized by the immune system as foreign, triggering an immune response. By targeting these neoantigens, cancer immunotherapy can be used to treat cancer. Companies in the Neoantigen market are focused on developing technologies to identify and develop neoantigens for use in cancer immunotherapy.
Companies in the Neoantigen market include Adaptive Biotechnologies, I-Mab, Neoantigen Therapeutics, NeoVax, and OncoImmune. Show Less Read more